Lyell Immunopharma (LYEL) EBIT (2020 - 2026)
Lyell Immunopharma recorded quarterly EBIT of -$44.3 million in Q1 2026, up 65.32% quarter-over-quarter from -$127.6 million in Q4 2025, and up 22.85% year-over-year from -$36.0 million in Q1 2025.
Lyell Immunopharma's EBIT history runs 7 years deep, the most recent figure standing at -$44.3 million for Q1 2026.
- In Q1 2026, EBIT rose 22.85% year-over-year to -$44.3 million; the TTM figure through Mar 2026 stood at -$256.3 million (up 28.91% YoY), while the FY2025 annual figure was -$269.4 million, up 24.91% from the prior year.
- EBIT came in at -$44.3 million for Q1 2026 at Lyell Immunopharma, up from -$127.6 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$14.8 million in Q4 2022 to a low of -$201.1 million in Q4 2024.
- A 5-year average of -$65.1 million and a median of -$57.4 million in 2025 frame the typical range for EBIT.
- Across the five-year window, EBIT surged 68.9% in 2022 and tumbled 302.52% in 2023, its largest moves.
- Lyell Immunopharma's EBIT stood at -$14.8 million in 2022, then sank by 302.52% to -$59.5 million in 2023, then tumbled by 238.02% to -$201.1 million in 2024, then surged by 36.54% to -$127.6 million in 2025, then jumped by 65.32% to -$44.3 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$44.3 million, -$127.6 million, and -$37.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -44.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.26 Mn |
| Dec 31, 2025 | -127.64 Mn |
| Sep 30, 2025 | -37.25 Mn |
| Jun 30, 2025 | -47.14 Mn |
| Mar 31, 2025 | -57.37 Mn |
| Dec 31, 2024 | -201.15 Mn |
| Sep 30, 2024 | -50.51 Mn |
| Jun 30, 2024 | -51.53 Mn |
| Mar 31, 2024 | -55.58 Mn |
| Dec 31, 2023 | -59.51 Mn |
| Sep 30, 2023 | -59.04 Mn |
| Jun 30, 2023 | -65.91 Mn |
| Mar 31, 2023 | -62.56 Mn |
| Dec 31, 2022 | -14.78 Mn |
| Sep 30, 2022 | -66.44 Mn |
| Jun 30, 2022 | -37.26 Mn |
| Mar 31, 2022 | -68.58 Mn |
| Dec 31, 2021 | -47.54 Mn |
| Sep 30, 2021 | -49.16 Mn |
| Jun 30, 2021 | -62.71 Mn |
| Mar 31, 2021 | -55.37 Mn |
| Dec 31, 2020 | -39.52 Mn |
| Sep 30, 2020 | -36.84 Mn |
| Jun 30, 2020 | -102.57 Mn |